You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 53 No. 2, February 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-Induced Remission of Depression

Heien L. Miller, MD; Pedro L. Delgado, MD; Ronald M. Salomon; Robert Berman, MD; John H. Krystal, MD; George R. Heninger, MD; Dennis S. Charney, MD

Arch Gen Psychiatry. 1996;53(2):117-128.


Abstract

Background
Most hypotheses of the therapeutic mechanism of action of antidepressant drugs have focused on the role of the monoamines. We examined the effect of catecholamine depletion on antidepressant-induced remission.

Method
The tyrosine hydroxylase inhibitor ct-methylparatyrosine and the antihistamine diphenhydramine hydrochloride were administered, during separate test sessions, to depressed patients in remission maintained with either norepinephrine reuptake inhibitors (desipramine [n=7] ormazindol [n=2]) or serotonin reuptake inhibitors (fluoxetine hydrochloride [n=9] or sertraline hydrochloride [n=l]). Because of considerable sedation associated with {alpha}-methylparatyrosine testing, diphenhydramine was used as an active control rather than an inactive placebo. The effects of {alpha}-methylparatyrosine and diphenhydramine on depression, anxiety, and plasma catecholamine metabolites were assessed.

Results
{alpha}-Methylparatyrosine produced similar significant decreases in plasma 3-methoxy-4-hydroxyphenyl-ethyleneglycol and homovanillic acid levels in the treatment groups. a-Methylparatyrosine produced a robust increase in depressive symptoms on the Hamilton Depression Rating Scale, including depressed mood, decreased concentration, anhedonia, loss of interest, and feelings of worthlessness, helplessness, and hopelessness, in the desipramine-mazindol but not in the fluoxetine-sertraline group. Diphenhydramine had no effects on mood in either treatment group.

Conclusions
The therapeutic effects of norepinephrine reuptake inhibitors, but not serotonin reuptake inhibitors, are reversed by catecholamine depletion. Considered with previous reports that serotonin depletion produces depressive relapses in patients in remission maintained with serotonin reuptake inhibitors, but not norepinephrine reuptake inhibitors, these findings suggest that antidepressants may not work via a single monoamine-related mechanism.



Author Affiliations

From the Department of Psychiatry, Yale University School of Medicine, New Haven, Conn, and the Department of Veterans Affairs Medical Center, West Haven, Conn.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neural Response to Catecholamine Depletion in Unmedicated Subjects With Major Depressive Disorder in Remission and Healthy Subjects
Hasler et al.
Arch Gen Psychiatry 2008;65:521-531.
ABSTRACT | FULL TEXT  

The Role of Dopamine in the Pathophysiology of Depression
Dunlop and Nemeroff
Arch Gen Psychiatry 2007;64:327-337.
FULL TEXT  

Antidepressant-Induced Increase in High-Affinity Rolipram Binding Sites in Rat Brain: Dependence on Noradrenergic and Serotonergic Function
Zhao et al.
J. Pharmacol. Exp. Ther. 2003;307:246-253.
ABSTRACT | FULL TEXT  

Regional Brain Metabolic Correlates of {alpha}-Methylparatyrosine-Induced Depressive Symptoms: Implications for the Neural Circuitry of Depression
Bremner et al.
JAMA 2003;289:3125-3134.
ABSTRACT | FULL TEXT  

The hypocretin/orexin system
Ebrahim et al.
JRSM 2002;95:227-230.
FULL TEXT  

Use of Dopamine-beta -hydroxylase-Deficient Mice to Determine the Role of Norepinephrine in the Mechanism of Action of Antidepressant Drugs
Cryan et al.
J. Pharmacol. Exp. Ther. 2001;298:651-657.
ABSTRACT | FULL TEXT  

Tryptophan depletion and its implications for psychiatry
BELL et al.
Br. J. Psychiatry 2001;178:399-405.
ABSTRACT | FULL TEXT  

Transient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker?
Berman et al.
Arch Gen Psychiatry 1999;56:395-403.
ABSTRACT | FULL TEXT  

Effects of Tryptophan Depletion vs Catecholamine Depletion in Patients With Seasonal Affective Disorder in Remission With Light Therapy
Neumeister et al.
Arch Gen Psychiatry 1998;55:524-530.
ABSTRACT | FULL TEXT  

A Molecular and Cellular Theory of Depression
Duman et al.
Arch Gen Psychiatry 1997;54:597-606.
ABSTRACT  

Decreased Serotonin Function in Bulimia Nervosa
Jimerson et al.
Arch Gen Psychiatry 1997;54:529-534.
ABSTRACT  

Effects of Tryptophan Depletion on Drug-Free Patients With Seasonal Affective Disorder During a Stable Response to Bright Light Therapy
Neumeister et al.
Arch Gen Psychiatry 1997;54:133-138.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.